Eleven biopharmaceutical companies have filed for bankruptcy so far in 2019, the most in a single year within the past decade, according to a new series fromBioPharma Dive.

Why it matters: Its rare for biotechs to go under because they have so much access to extra funding. But more firms have hit dead ends.

Between the lines: The reasons for the biotech bankruptcies run the gamut, but in general, all of the companies burn cash at a high rate.

Why you'll hear about this again: "You're probably going to see more of these situations going forward, where a company is preclinical, went public and is left on their own and has to raise additional money from the public markets, and they flounder," the CEO of a bankrupt biotech firm told BioPharma Dive.

Go deeper:

Read the original:

11 biotechnology companies have filed for bankruptcy so far in 2019 - Axios